PMV Pharmaceuticals (PMVP) has filed a new preliminary prospectus for an IPO of 11.765M common shares (from 7.350M) at $16-18. Gross proceeds should be ~$200M at the midpoint.
The Cranbury, NJ-based biotech develops small molecule tumor-agnostic therapies targeting mutations in a tumor suppressor protein called p53 which has the ability to eliminate cancer cells in its normal or wild-type state. The lead candidate is PC14586, designed to correct p53 misfolding caused by a specific mutation called Y220C that is associated with 1.0-1.5% of all cancers. A Phase 1/2 study should launch in H2.
https://seekingalpha.com/news/3616929-pmv-pharmaceuticals-files-for-upsized-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.